Vanguard Group Inc. Has $113.27 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Vanguard Group Inc. cut its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 5.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,590,974 shares of the company's stock after selling 292,411 shares during the period. Vanguard Group Inc. owned approximately 9.69% of Twist Bioscience worth $113,273,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. BlackRock Inc. grew its stake in shares of Twist Bioscience by 11.1% in the 2nd quarter. BlackRock Inc. now owns 6,905,031 shares of the company's stock valued at $141,277,000 after buying an additional 691,590 shares during the period. State Street Corp grew its stake in shares of Twist Bioscience by 19.2% in the 1st quarter. State Street Corp now owns 5,275,841 shares of the company's stock valued at $79,560,000 after buying an additional 849,592 shares during the period. Capital World Investors grew its stake in shares of Twist Bioscience by 6.0% in the 1st quarter. Capital World Investors now owns 4,795,848 shares of the company's stock valued at $236,819,000 after buying an additional 273,148 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Twist Bioscience by 4.2% in the 1st quarter. JPMorgan Chase & Co. now owns 4,057,312 shares of the company's stock valued at $61,185,000 after buying an additional 162,161 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Twist Bioscience by 10.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,258,394 shares of the company's stock valued at $43,993,000 after buying an additional 120,489 shares during the period.

Analyst Ratings Changes

TWST has been the subject of a number of analyst reports. Barclays lifted their price target on Twist Bioscience from $30.00 to $45.00 and gave the company an "overweight" rating in a research note on Thursday, January 25th. Scotiabank lifted their price target on Twist Bioscience from $30.00 to $43.00 and gave the company a "sector outperform" rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and lifted their price target for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded down $1.36 during midday trading on Thursday, reaching $31.98. The company's stock had a trading volume of 701,798 shares, compared to its average volume of 942,092. Twist Bioscience Co. has a 12-month low of $11.46 and a 12-month high of $43.21. The firm has a 50 day moving average price of $36.45 and a 200-day moving average price of $29.19. The stock has a market capitalization of $1.85 billion, a P/E ratio of -8.86 and a beta of 1.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The firm had revenue of $71.50 million for the quarter, compared to the consensus estimate of $67.59 million. During the same quarter in the previous year, the business earned ($0.74) EPS. The company's revenue was up 31.8% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience Co. will post -3.17 EPS for the current year.

Insider Buying and Selling

In related news, Director Robert Chess sold 4,110 shares of Twist Bioscience stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now owns 64,169 shares of the company's stock, valued at approximately $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,132 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the sale, the chief executive officer now owns 514,149 shares of the company's stock, valued at approximately $16,833,238.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Chess sold 4,110 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares in the company, valued at approximately $2,244,631.62. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,481 shares of company stock valued at $365,655. 3.92% of the stock is owned by company insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.